Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 227   Home Print this page  Email this page Small font size Default font size Increase font size

  Table of Contents    
Year : 2012  |  Volume : 29  |  Issue : 4  |  Page : 395  

Authors' reply

1 Department of Pulmonary Medicine, J. L. N. Medical College, Ajmer, Rajasthan, India
2 Department of Pharmacology, J. L. N. Medical College, Ajmer, Rajasthan, India

Date of Web Publication23-Oct-2012

Correspondence Address:
Ramakant Dixit
Department of Pulmonary Medicine, J. L. N. Medical College, Ajmer, Rajasthan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

How to cite this article:
Dixit R, George J, Sharma AK. Authors' reply. Lung India 2012;29:395

How to cite this URL:
Dixit R, George J, Sharma AK. Authors' reply. Lung India [serial online] 2012 [cited 2020 Mar 28];29:395. Available from: http://www.lungindia.com/text.asp?2012/29/4/395/102850


We thank Dr. P. R. Gupta [1] for his interest in our article published in Lung India (January-March 2012). [2] Although there are increasing reports on thrombocytopenia during rifampicin therapy, [3] the occurrence is mostly observed during intermittent therapy compared to daily therapy with rifampicin. The same opinion is also shared by other authors also. [4],[5] In an article of "letter to editor" format, it is not always possible to cite each and every previously published report on the same topic due to space constraint, unlike a "review article." More so, the technical corrections of most journals now-a-days ask for recent references to replace the older ones. Therefore, these unintentional lacunae cannot be viewed as poor search of the literature. Our article was also to stress upon the casual relationship between thrombocytopenia and rifampicin with the evidence by standardized assessment such as WHO-UMC Casualty system or Naranjo ADR Probability scale. [6],[7] There are still fewer published reports describing these tools in their experience on thrombocytopenia during daily rifampicin therapy. [2],[4] As well said and agreed, thrombocytopenia is a serious and life-threatening complication, and our report also illustrates the danger of noncompliance during tuberculosis treatment.

   References Top

1.Gupta PR. Thronbocytopenia due to rifampicin. Lung India 2012;29:394.  Back to cited text no. 1
2.Dixit R, George J, Sharma AK. Thronbocytopenia due to rifampicin. Lung India 2012;29:90-2.  Back to cited text no. 2
[PUBMED]  Medknow Journal  
3.Agrawal A, Gutch M, Jain N, Singh A. Do not miss rifampicin induced thrombocytopenic purpura. BMJ Case Rep 2012;2012:pii: bcr1220115282.  Back to cited text no. 3
4.Garg R, Gupta V, Mehra S, Singh R, Prasad R. Rifampicin induced thrombocytopenia. Indian J Tuberc 2007;54:94-6.  Back to cited text no. 4
5.Verma AK, Singh A, Chandra A, Kumar S, Gupta RK. Rifampicin-induced thrombocytopenia. Indian J Pharmacol 2010;42:240-2.  Back to cited text no. 5
[PUBMED]  Medknow Journal  
6.The use of the WHO-UMC system for standardised case causality assessment. Available from: http://www.who-umc.org/graphics/4409.pdf [Last accessed on 2011 Feb 12].  Back to cited text no. 6
7.Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.  Back to cited text no. 7


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded171    
    Comments [Add]    

Recommend this journal